BPOM Waits For US FDA Research On Pfizer Vaccines For Children In Indonesia

Head of BPOM RI Penny K Lukito after opening the Frozen Food UMK Mentoring Week during the Pandemic at the Shangri-La Hotel, Jakarta, Tuesday, November 2 (Andi Firdaus/Antara)

JAKARTA - The Food and Drug Supervisory Agency (BPOM) is still waiting for the results of the United States Food and Drug Administration (US FDA) research on the use of the Pfizer vaccine for the child age group in Indonesia. is waiting for registration. BPOM cannot immediately give permission," said Head of BPOM RI Penny K Lukito after opening the Frozen Food UMK Assistance Week during the Pandemic Period at the Shangri-La Hotel, Jakarta, reported by Antara, Tuesday, November 2.

Penny said the US FDA had the capacity to issue strict standards for COVID-19 vaccine products which could be the basis for BPOM RI to grant permission to use Pfizer in Indonesia. Sinovac type.

Vaccination of children, said Penny, is important to realize apart from the risk factors as carriers of the virus, the age of children is also being faced with face-to-face school policies. Penny said the COVID-19 vaccination could give parents the confidence to give permission for their children to attend school face-to-face.